Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease–Parkinson's disease overlap?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD), the most common form of dementia, is characterized histopathologically by the deposition of β-amyloid (Aβ) plaques and neurofibrillary tangles-containing hyperphosphorylated tau protein in the brain. Parkinson’s disease (PD), the most common movement disorder, is characterized by the aggregation of α-synuclein protein in Lewy body inclusions and the death of dopaminergic neurons in the substantia nigra. Based on their pathological signatures, AD and PD can be considered as two different disease entities. However, a subpopulation of PD patients also exhibit Aβ plaques, and AD patients exhibit α-synuclein aggregates. This overlap between PD and AD suggests that common pathological pathways exist for the two diseases. Identification of factors and cellular mechanisms by which these factors can trigger pathological hallmarks for AD/PD overlap may help in designing disease-modifying therapies that can reverse or stop the progression of AD and PD. For the last decade, work in our laboratory has shown that fluctuations in the levels of cholesterol oxidation products (oxysterols) may correlate with the onset of AD and PD. In this review, we will provide results from our laboratory and data from literature that converge to strongly suggest the involvement of cholesterol and cholesterol oxidation products in the pathogenesis of AD and PD. We will specifically delineate the role of and the underlying mechanisms by which increased levels of the oxysterol 27-hydroxycholesterol contribute to the pathogenesis of AD, PD, and AD/PD overlap.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Sidén, A., Diczfalusy, U., & Björkhem, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9799 · Cited by 682
Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557 · cited 1×
“A report from an epidemiological study on a large cohort of women and men has demonstrated that high cholesterol levels during mid-life are associated with a 66% increase in AD risk late in life (Solomon et al., 2009).”
BackgroundBazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441 · cited 1×
“There is also increasing evidence that saturated free fatty acids (FFA) increase the risk of AD (Bazan et al., 2011).”
BackgroundAssociations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267 · cited 2×
“Indeed, high LDL-C and low HDL-C levels were found to be associated with cerebral amyloidosis in humans (Reed et al., 2014), and high HDL-C levels have also been shown to correlate with a lower risk of late onset AD in elderly individuals (Reitz et al.”
BackgroundLewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177 · cited 1×
“The distribution of Lewy bodies in AD occurs mostly in the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD (Kotzbauer et al., 2001; Choi et al., 2012).”
BackgroundDietary fats, cholesterol and iron as risk factors for Parkinson's disease
Powers, K. M., Smith-Weller, T., Franklin, G. M., Longstreth, W. T., Swanson, P. D., & Checkoway, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.03.002 · Cited by 100 · cited 2×
“In other studies however, elevated serum levels of cholesterol were either not associated with PD risk (de Lau et al. 2005) or were related to a decreased PD risk (Powers et al. 2009).”
Background
Cited by
The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson’s Disease
Galvagnion, C. (2017) · Journal of Parkinson's Disease · doi:10.3233/jpd-171103 · Cited by 258
Loera-Valencia, R., Goikolea, J., Parrado-Fernandez, C., Merino-Serrais, P., & Maioli, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.003 · Cited by 214
Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease
Gamba, P., Testa, G., Gargiulo, S., Staurenghi, E., Poli, G., & Leonarduzzi, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00119 · Cited by 180
The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer’s Disease
Gamba, P., Giannelli, S., Staurenghi, E., Testa, G., Sottero, B., Biasi, F., Poli, G., & Leonarduzzi, G. (2021) · Antioxidants · doi:10.3390/antiox10050740 · Cited by 70
Cholesterol Dysmetabolism in Alzheimer’s Disease: A Starring Role for Astrocytes?
Staurenghi, E., Giannelli, S., Testa, G., Sottero, B., Leonarduzzi, G., & Gamba, P. (2021) · Antioxidants · doi:10.3390/antiox10121890 · Cited by 44
Engel, D. F., Grzyb, A. N., de Oliveira, J., Pötzsch, A., Walker, T. L., Brocardo, P. S., Kempermann, G., & de Bem, A. F. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.002 · Cited by 33
Yamchuen, P., Jeenapongsa, R., Nudmamud-Thanoi, S., & Limpeanchob, N. (2017) · Biologia · doi:10.1515/biolog-2017-0024 · Cited by 2
Metadata
- Authors
- Marwarha, G., & Ghribi, O.
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 68
- Pages
- 13-18
- ISSN
- 0531-5565 (ISSN-L)
- OpenAlex
- W2016512153
- Cited by
- 87
- References
- 6
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.